Renaissance Technologies
CLRB icon

Renaissance Technologies’s Cellectar Biosciences CLRB Stock Holding History

Renaissance Technologies’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-24,900
Closed -$139K – 3295
2025
Q3 		$139K Buy
+24,900
New +$123K ﹤0.01% 3209
2024
Q2 		– Sell
-3,283
Closed -$392K – 3544
2024
Q1 		$392K Buy
+3,283
New +$356K ﹤0.01% 2969
2023
Q4 		– Sell
-723
Closed -$57K – 3782
2023
Q3 		$57K Sell
723
-1,410
-66% -$83K ﹤0.01% 3376
2023
Q2 		$125K Buy
2,133
+220
+12% +$10.6K ﹤0.01% 3421
2023
Q1 		$82K Buy
1,913
+355
+23% +$17.3K ﹤0.01% 3548
2022
Q4 		$80K Buy
1,558
+968
+164% +$58K ﹤0.01% 3689
2022
Q3 		$59K Buy
590
+35
+6% +$5.03K ﹤0.01% 3711
2022
Q2 		$67K Buy
555
+132
+31% +$18.9K ﹤0.01% 3942
2022
Q1 		$87K Buy
423
+23
+6% +$4.03K ﹤0.01% 3819
2021
Q4 		$80K Sell
400
-1,090
-73% -$262K ﹤0.01% 3717
2021
Q3 		$414K Sell
1,490
-1,881
-56% -$574K ﹤0.01% 2955
2021
Q2 		$1.2M Buy
3,371
+396
+13% +$172K ﹤0.01% 2571
2021
Q1 		$1.44M Buy
2,975
+2,072
+229% +$1.23M ﹤0.01% 2420
2020
Q4 		$563K Sell
903
-568
-39% -$261K ﹤0.01% 2766
2020
Q3 		$547K Sell
1,471
-1,164
-44% -$460K ﹤0.01% 2784
2020
Q2 		$1.01M Buy
2,635
+1,861
+240% +$781K ﹤0.01% 2530
2020
Q1 		$309K Buy
774
+111
+17% +$74.3K ﹤0.01% 2967
2019
Q4 		$448K Buy
663
+73
+12% +$38K ﹤0.01% 2945
2019
Q3 		$354K Buy
590
+180
+44% +$117K ﹤0.01% 2985
2019
Q2 		$268K Buy
410
+221
+117% +$151K ﹤0.01% 3214
2019
Q1 		$133K Sell
189
-1
-0.5% -$609 ﹤0.01% 3267
2018
Q4 		$88K Sell
190
-5
-3% -$3.56K ﹤0.01% 3248
2018
Q3 		$176K Buy
+195
New +$230K ﹤0.01% 3171

Other funds holding CLRB

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
RCA
Riverview Capital Advisers Boston, Massachusetts $300M AUM 10.98% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies's CLRB Position: Q4 2025 in Review

Renaissance Technologies sold out of Cellectar Biosciences (CLRB) in Q4 2025, closing a stake of 24,900 shares — an estimated $139K sold.

Renaissance Technologies first reported a position in CLRB in Q3 2018 and held it in 23 quarters. The position peaked at $1.44M in Q1 2021. 20 funds tracked by Wall St. Rank hold CLRB as of Q4 2025.

  • Renaissance Technologies reported no remaining Cellectar Biosciences position as of Q4 2025 after selling out during the quarter.
  • Renaissance Technologies sold 24,900 Cellectar Biosciences shares in Q4 2025, an estimated $139K.
  • Renaissance Technologies first reported a position in Cellectar Biosciences in Q3 2018 and held it in 23 quarters.
  • Renaissance Technologies's Cellectar Biosciences position peaked at $1.44M in Q1 2021.
  • 20 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q4 2025.

Based on Renaissance Technologies's 13F filing for Q4 2025, filed 12 Feb 2026.